|Bid||18.59 x 900|
|Ask||19.30 x 800|
|Day's range||17.88 - 19.01|
|52-week range||15.45 - 33.31|
|Beta (5Y monthly)||1.18|
|PE ratio (TTM)||N/A|
|Earnings date||26 Feb 2024 - 01 Mar 2024|
|Forward dividend & yield||N/A (N/A)|
|1y target est||50.31|
The consensus price target hints at a 163.8% upside potential for Denali Therapeutics Inc. (DNLI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Flagship Pioneering, the bioplatform innovation company, today unveiled Quotient Therapeutics, a company pioneering somatic genomics, the study of genetic variation at the cellular level, to discover therapeutics informed by new links between genes and disease. Flagship has made an initial commitment of $50 million to advance development of the company's platform following two years of development at Flagship Labs and pursue a pipeline of medicines across a wide range of therapeutic areas and mo
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 13.25% and 88.33%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?